We are studying the safety and feasibility of new CART cell therapies for children and young adults with relapsed or refractory acute lymphoblastic leukemia. This trial aims to find better treatment options for those who have not responded to current therapies.
Health conditions and diseases that the clinical trial is designed to study and treat.
Acute Lymphoblastic Leukemia (ALL) is a fast-growing cancer of the blood and bone marrow that primarily affects children and young adults, characterized by the overproduction of immature white blood cells. When it is refractory or relapsed, it means the leukemia has not responded to treatment or has returned after treatment.
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.